MARC ayrıntıları
| 000 -LEADER |
|---|
| fixed length control field |
naa a22 7ar4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20150602094728.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
150427t xxu||||| |||| 00| 0 tu d |
| 001 - CONTROL NUMBER |
|---|
| control field |
264652 |
| 016 ## - NATIONAL BIBLIOGRAPHIC AGENCY CONTROL NUMBER |
|---|
| Record control number |
WOS:000347269300001 |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
|---|
| International Standard Serial Number |
0197-0186 |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
NEU |
| 041 ## - LANGUAGE CODE |
|---|
| Language code of text/sound track or separate title |
eng |
| 050 04 - LIBRARY OF CONGRESS CALL NUMBER |
|---|
| Classification number |
WL 140 |
| 100 1# - MAIN ENTRY--PERSONAL NAME |
|---|
| 9 (RLIN) |
573261 |
| Personal name |
Yildirim, Fatos Belgin. |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Mechanism of the beneficial effect of melatonin in experimental Parkinson's disease |
| Statement of responsibility, etc. |
Fatos Belgin Yildirim, Ozlem Ozsoy, Gamze Tanriover, Yasemin Kaya, Eren Ogut, Burcu Gemici, Sayra Dilmac, Ayse Ozkan, Aysel Agar, Mutay Aslan. |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Place of publication, distribution, etc. |
Pergamon-Elsevier Science Ltd., |
| Date of publication, distribution, etc. |
2014. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
This study aimed to elucidate locomotor activity changes in 6-hydroxydopamine (6-OHDA) induced Parkinson's disease (PD) and investigate the possible beneficial effects of melatonin on altered levels of locomotor activity, cyclooxygenase (COX), prostaglandin E2 (PGE2), nuclear factor kappa-B (NF-kappa B), nitrate/nitrite and apoptosis. Male Wistar rats were divided into five groups: vehicle (V), melatonin-treated (M), 6-OHDA-injected (6-OHDA), 6-OHDA-injected + melatonin-treated (6-OHDA-Mel) and melatonin treated + 6-OHDA-injected (Mel-6-OHDA). Melatonin was administered intraperitoneally at a dose of 10 mg/kg/day for 30 days in M and Mel-6-OHDA groups, for 7 days in 6-OHDA-Mel group. Experimental PD was created stereotactically via unilateral infusion of 6-OHDA into the medial forebrain bundle (MFB). The 6-OHDA-Mel group started receiving melatonin when experimental PD was created and treatment was continued for 7 days (post-treatment). In the Mel-6-OHDA group, experimental PD was created on the 23rd day of melatonin treatment and continued for the remaining 7 days (pre- and post-treatment). Locomotor activity performance decreased in 6-OHDA group compared with vehicle; however melatonin treatment did not improve this impairment. Nuclear factor kappa Bp65 and Bcl-2 levels were significantly decreased while COX, PGE2 and caspase-3 activity were significantly increased in 6-OHDA group. Melatonin treatment significantly decreased COX, PGE2 and caspase-3 activity, increased Bcl-2 and had no effect on NE-kappa B levels in experimental PD. 6-Hydroxydopamine injection caused an obvious reduction in TH positive dopaminergic neuron viability as determined by immunohistochemistry. Melatonin supplementation decreased dopaminergic neuron death in 6-OHDA-Mel and Mel-6-OHDA groups compared with 6-OHDA group. Melatonin also protected against 6-OHDA-induced apoptosis, as identified by increment in Bcl-2 levels in dopaminergic neurons. The protective effect of melatonin was more prominent for most parameter following 30 days treatment (pre- and post-) than 7 days post-treatment. In summary, melatonin treatment decreased dopaminergic neuron death in experimental PD model by increasing Bcl-2 protein level and decreasing caspase-3 activity. (C) 2014 Elsevier Ltd. All rights reserved. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| 9 (RLIN) |
124265 |
| Topical term or geographic name entry element |
Neurology |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| 9 (RLIN) |
572720 |
| Topical term or geographic name entry element |
Near East University Article |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| 9 (RLIN) |
572723 |
| Topical term or geographic name entry element |
Yakın Doğu Üniversitesi Makale |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| 9 (RLIN) |
573262 |
| Topical term or geographic name entry element |
Melatonin |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| 9 (RLIN) |
573263 |
| Topical term or geographic name entry element |
6-Hydroxydopamine |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| 9 (RLIN) |
573264 |
| Topical term or geographic name entry element |
Cyclooxygenase |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| 9 (RLIN) |
573265 |
| Topical term or geographic name entry element |
Nf-Kappa-B |
| 773 ## - HOST ITEM ENTRY |
|---|
| Related parts |
DEC 2014 , Vol 79, p1-11 |
| International Standard Serial Number |
01970186 |
| Title |
Neurochemistry International |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| Uniform Resource Identifier |
<a href="http://library.neu.edu.tr:2048/login?url=http://dx.doi.org/10.1016/j.neuint.2014.09.005 ">http://library.neu.edu.tr:2048/login?url=http://dx.doi.org/10.1016/j.neuint.2014.09.005 </a> |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| -- |
1000007 |
| Call number prefix |
WL0000140M432014 |
| Koha item type |
Online Electronic Document |
